Hetrombopag to prevent low platelets after lung cancer chemotherapy
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a medicine called hetrombopag that may help raise your platelet count after chemotherapy for advanced lung cancer. It aims to prevent dangerously low platelet levels so you can continue your cancer treatment more safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have lung cancer that has spread to other parts of the body.
- You are getting chemotherapy that includes platinum or gemcitabine, given in 21-day cycles, and you plan to have at least 2 more cycles.
- Your platelet count dropped below 75 after your last chemotherapy, and it is now between 100 and 200 before this new treatment starts.
- You are generally able to care for yourself (ECOG score 0-2) and are expected to live at least 3 more months.
- Your organs (like bone marrow, liver, and kidneys) are working well enough, and you have no other serious health issues like blood clots or bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether avatrombopag can help your platelet count recover after a bone marrow transplant from an unrelated donor (UCBT) in certain bone marrow failure diseases. If platelets recover better, it may reduce risks related to low platelets after transplant.
This study tests an oral medication, hetrombopag, to see if it can safely raise platelet counts in people with gynecologic cancers whose platelets drop too low from chemotherapy or other cancer treatments. It may help them continue their cancer therapy without delays or bleeding risks.
This trial tests whether a drug called hetrombopag can prevent dangerously low platelet counts (cells that help blood clot) in breast cancer patients receiving chemotherapy. It is for people who experienced very low platelets from a previous round of treatment.
This study tests a medication called hetrombopag, which helps raise platelet counts. It's for people with acute myeloid leukemia who have low platelets after intensive chemotherapy and are in remission.
This trial tests if hetrombopag can prevent low platelet counts caused by chemotherapy in people with gastrointestinal cancers. It may help reduce the risk of bleeding and the need for platelet transfusions.
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.